{"componentChunkName":"component---src-templates-study-details-page-js","path":"/en/study/A4001063","result":{"data":{"studyNotFoundJson":{"title":"Study not found","content":{"childMarkdownRemark":{"html":"<p>If you entered a web address please check it was correct.</p>\n<p>You can also try <a href=\"/en/studies\">Search Page</a> to find the study you are looking for.</p>"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"<p>A unique number for a study given by ViiV.</p>"}},"ctGov":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.</p>"}},"eudraCT":{"childMarkdownRemark":{"html":"<p>This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.</p>"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT00478231","ctis_id":"","HasResults":"true","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":""},"PatientLevelData":"false","SharingIpd":"","acronym":"","allocation":"Non-randomized","arm_groups":[{"arm_group_label":"1","arm_group_description":"","arm_type":"Experimental"}],"assignment":"Single Group Assignment","brief_summary":"To collect safety and tolerability data in a more diverse patient population of patients with HIV/Aids, who have limited therapeutic options.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Multicenter, Safety Study Of Maraviroc","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Acquired Immunodeficiency Syndrome","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:57:52","criteria":"Inclusion Criteria: - Subjects with limited or no approved treatment options available to them due to resistance or intolerance; - Subjects must be failing to achieve adequate virologic suppression on their current regimen and have HIV-1 RNA ≥ 1000 copies/ml, at screening. - Have only R5 HIV-1 at Screening as verified by the Monogram Biosciences Trofile assay. Exclusion Criteria: - Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trials or having previously discontinued Maraviroc in trials - Potentially life threatening (Grade 4) laboratory abnormality or medical condition (according to the Division of AIDS table for grading severity of adult adverse experiences) still under investigation unless a diagnosis has been established and felt not to affect risk/benefit assessment or eventual interpretation of safety results, based on discussion between the investigator and Pfizer.","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 3","display_phase_internal":"PHASE_3","display_status":"Completed","display_status_internal":"RECSTATUS_I_COMPLETED","endpoint":"","enrollment":"209","exclusion":"","gender":"Both","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"1ef588ab-91c0-54e1-a4c1-1bf9ddaa9024","internal":{"content":null,"contentDigest":"3cfed2721941722c4acc6ee305c51187","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Subjects with limited or no approved treatment options available to them due to resistance or intolerance; - Subjects must be failing to achieve adequate virologic suppression on their current regimen and have HIV-1 RNA ≥ 1000 copies/ml, at screening. - Have only R5 HIV-1 at Screening as verified by the Monogram Biosciences Trofile assay. Exclusion Criteria: - Failed prior treatment with any CCR5 antagonist, in any ongoing CCR5 trials or having previously discontinued Maraviroc in trials - Potentially life threatening (Grade 4) laboratory abnormality or medical condition (according to the Division of AIDS table for grading severity of adult adverse experiences) still under investigation unless a diagnosis has been established and felt not to affect risk/benefit assessment or eventual interpretation of safety results, based on discussion between the investigator and Pfizer.","interventions":[{"arm_group_label":"1","intervention_description":"Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.","intervention_name":"Maraviroc","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":false,"keywords":["Multicenter","Open Label","Non-Comparative Safety Study Of Maraviroc"],"last_follow_up_date":"09/01/2010 00:00:00","links":[{"description":"To obtain contact information for a study center near you, click here.","url":"https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A4001063&StudyName=Multicenter%2C%20Safety%20Study%20Of%20Maraviroc"},{"description":"Link to ClinicalStudyResults.org","url":"http://www.clinicalstudyresults.org/drugdetails/?study_name=A4001063&sort=c.company_name&page=1&drug_id=11542"}],"locations":[{"City":"São Paulo","Latitude":"-23.6082285","CountryDisplay":"Brazil","Longitude":"-46.5958995","Name":"Pfizer Investigational Site","StateDisplay":"SP","PostalCode":"04231-030","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Campinas","Latitude":"-22.829593","CountryDisplay":"Brazil","Longitude":"-47.0619319","Name":"Pfizer Investigational Site","StateDisplay":"SP","PostalCode":"13083-887","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Florianopolis","Latitude":"-27.5749618","CountryDisplay":"Brazil","Longitude":"-48.5370125","Name":"Pfizer Investigational Site","StateDisplay":"SC","PostalCode":"88025-301","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Nova Iguaçu","Latitude":"-22.7110504","CountryDisplay":"Brazil","Longitude":"-43.4489612","Name":"Pfizer Investigational Site","StateDisplay":"RJ","PostalCode":"26030-380","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Salvador","Latitude":"-12.9915919","CountryDisplay":"Brazil","Longitude":"-38.5201354","Name":"Pfizer Investigational Site","StateDisplay":"BA","PostalCode":"40110-160","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sao Paulo","Latitude":"-23.5564727","CountryDisplay":"Brazil","Longitude":"-46.6669183","Name":"Pfizer Investigational Site","StateDisplay":"SP","PostalCode":"01246-900","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Curitiba","Latitude":"-25.4501391","CountryDisplay":"Brazil","Longitude":"-49.2920649","Name":"Pfizer Investigational Site","StateDisplay":"PR","PostalCode":"80240-280","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Belo Horizonte","Latitude":"-19.9255726","CountryDisplay":"Brazil","Longitude":"-43.9295202","Name":"Pfizer Investigational Site","StateDisplay":"MG","PostalCode":"30130-100","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sao Paulo","Latitude":"-23.5532037","CountryDisplay":"Brazil","Longitude":"-46.651978","Name":"Pfizer Investigational Site","StateDisplay":"SP","PostalCode":"01307-001","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sao Paulo","Latitude":"-23.5995941","CountryDisplay":"Brazil","Longitude":"-46.6414208","Name":"Pfizer Investigational Site","StateDisplay":"SP","PostalCode":"04040-002","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Brasilia","Latitude":"-15.8101237","CountryDisplay":"Brazil","Longitude":"-47.9047223","Name":"Pfizer Investigational Site","StateDisplay":"DF","PostalCode":"70351-580","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ribeirao Preto","Latitude":"-21.1704008","CountryDisplay":"Brazil","Longitude":"-47.8103238","Name":"Pfizer Investigational Site","StateDisplay":"SP","PostalCode":"14048900","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Porto Alegre","Latitude":"-30.0587055","CountryDisplay":"Brazil","Longitude":"-51.2270282","Name":"Pfizer Investigational Site","StateDisplay":"RS","PostalCode":"90110-270","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Sao Paulo","Latitude":"-23.5975558","CountryDisplay":"Brazil","Longitude":"-46.6269553","Name":"Pfizer Investigational Site","StateDisplay":"SP","PostalCode":"04121-000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Santo Andre","Latitude":"-23.6609793","CountryDisplay":"Brazil","Longitude":"-46.5507207","Name":"Pfizer Investigational Site","StateDisplay":"SP","PostalCode":"09060-650","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Campinas","Latitude":"-22.9099384","CountryDisplay":"Brazil","Longitude":"-47.0626332","Name":"Pfizer Investigational Site","StateDisplay":"SP","PostalCode":"13059-900","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"Open Label","maximum_age_raw":"N/A N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 Years","modified_date":"10/01/2018 22:53:06","number_of_arms":"1","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"A Multicenter, Open Label, Non-Comparative Safety Study Of Maraviroc","org_study_id":"A4001063","overall_contact":{"email":null,"last_name":"Pfizer CT.gov Call Center","phone":"1-800-718-1021"},"overall_status":"Completed - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"Phase 3","primary_compl_date":"08/01/2010 00:00:00","primary_outcomes":[],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"None","lead_sponsor":"ViiV Healthcare","collaborators":["Pfizer"]},"start_date":"07/01/2007 00:00:00","study_type":"Interventional","therapeutic_area":"","citations":[],"is_section_801":true}},"pageContext":{"studyId":"A4001063"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}